MX2023010925A - Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables. - Google Patents
Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.Info
- Publication number
- MX2023010925A MX2023010925A MX2023010925A MX2023010925A MX2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A
- Authority
- MX
- Mexico
- Prior art keywords
- risperidone
- injectable formulation
- biodegradable polymers
- long acting
- acting injectable
- Prior art date
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001534 risperidone Drugs 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 229920002988 biodegradable polymer Polymers 0.000 title 1
- 239000004621 biodegradable polymer Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 229920000359 diblock copolymer Polymers 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920000428 triblock copolymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162272P | 2021-03-17 | 2021-03-17 | |
| IB2021052248 | 2021-03-17 | ||
| US202163208860P | 2021-06-09 | 2021-06-09 | |
| US202163270174P | 2021-10-21 | 2021-10-21 | |
| PCT/EP2022/057009 WO2022195018A1 (en) | 2021-03-17 | 2022-03-17 | Long acting injectable formulation comprising risperidone and biodegradable polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010925A true MX2023010925A (es) | 2023-09-27 |
Family
ID=81307068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010925A MX2023010925A (es) | 2021-03-17 | 2022-03-17 | Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240148641A1 (enExample) |
| EP (1) | EP4308077A1 (enExample) |
| JP (1) | JP2024511353A (enExample) |
| KR (1) | KR20230158088A (enExample) |
| AU (1) | AU2022236485A1 (enExample) |
| BR (1) | BR112023018652A2 (enExample) |
| CA (1) | CA3208006A1 (enExample) |
| IL (1) | IL304980A (enExample) |
| MX (1) | MX2023010925A (enExample) |
| WO (1) | WO2022195018A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026501805A (ja) * | 2023-01-10 | 2026-01-16 | メドインセルル エス．エー． | オランザピン組成物及び使用の方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012010195A2 (pt) * | 2009-10-30 | 2016-04-26 | Janssen Pharmaceutica Nv | regime de dosagem associado a ésteres de paliperidona injetável de longa ação |
| US10463607B2 (en) * | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| KR101424163B1 (ko) * | 2010-12-24 | 2014-08-01 | 주식회사 삼양바이오팜 | 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법 |
| US9023897B2 (en) * | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| EP2866837B1 (en) | 2012-06-27 | 2022-12-14 | Medincell S.A. | Biodegradable drug delivery for hydrophobic compositions |
| US20190015415A1 (en) * | 2015-09-30 | 2019-01-17 | Indivior Uk Limited | Methods for treating schizophrenia |
| CN107213136B (zh) * | 2017-06-07 | 2021-06-01 | 广州帝奇医药技术有限公司 | 一种长效缓释药物制剂及其制备方法 |
| WO2020154315A1 (en) * | 2019-01-22 | 2020-07-30 | Indivior Uk Limited | Methods for treating schizophrenia |
| MX2022003051A (es) * | 2019-09-13 | 2022-06-14 | Medincell S A | Formulaciones para la administracion de farmacos. |
-
2022
- 2022-03-17 JP JP2023556936A patent/JP2024511353A/ja active Pending
- 2022-03-17 IL IL304980A patent/IL304980A/en unknown
- 2022-03-17 KR KR1020237035519A patent/KR20230158088A/ko active Pending
- 2022-03-17 CA CA3208006A patent/CA3208006A1/en active Pending
- 2022-03-17 US US18/281,392 patent/US20240148641A1/en active Pending
- 2022-03-17 WO PCT/EP2022/057009 patent/WO2022195018A1/en not_active Ceased
- 2022-03-17 BR BR112023018652A patent/BR112023018652A2/pt unknown
- 2022-03-17 MX MX2023010925A patent/MX2023010925A/es unknown
- 2022-03-17 AU AU2022236485A patent/AU2022236485A1/en active Pending
- 2022-03-17 EP EP22716046.2A patent/EP4308077A1/en active Pending
-
2024
- 2024-02-23 US US18/585,349 patent/US12329851B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023018652A2 (pt) | 2023-10-03 |
| AU2022236485A1 (en) | 2023-08-24 |
| US12329851B2 (en) | 2025-06-17 |
| EP4308077A1 (en) | 2024-01-24 |
| WO2022195018A1 (en) | 2022-09-22 |
| JP2024511353A (ja) | 2024-03-13 |
| US20240148641A1 (en) | 2024-05-09 |
| KR20230158088A (ko) | 2023-11-17 |
| US20240325293A1 (en) | 2024-10-03 |
| CA3208006A1 (en) | 2022-09-22 |
| IL304980A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| LTPA2008007I1 (lt) | N-pakeisti hidroksipirimidinono karboksamido ŽIV integrazės inhibitoriai | |
| WO2002004001A3 (en) | A composition for the delivery of live cells and methods of use | |
| SI1441734T1 (sl) | Dihidropirimidin karboksamidni inhibitorji HIV-integraze | |
| MX2022003051A (es) | Formulaciones para la administracion de farmacos. | |
| WO2022173888A8 (en) | Pharmaceutically acceptable salts of psilocin and uses thereof | |
| MX2023012723A (es) | Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares. | |
| MX2023010925A (es) | Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables. | |
| DK1528931T3 (da) | Dipeptidylpeptidase-IV-inhibitorer til reduktion af hastigheden af kronisk vægtforögelse | |
| MX2025008012A (es) | Composiciones de olanzapina y metodos de uso | |
| WO2023196832A3 (en) | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections | |
| MX2021011727A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| NZ594154A (en) | Transdermal administration of buprenorphine for preoperative treatment of post operative pain | |
| PH12022552645A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases | |
| NZ778435A (en) | Pharmaceutical compositions comprising meloxicam | |
| ATE359800T1 (de) | Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose | |
| ZA202202673B (en) | Methods and compositions for treating endometriosis | |
| MX2026001798A (es) | Metodo para tratar o prevenir enfermedades relacionadas con el colesterol utilizando un inhibidor de pcsk9 | |
| MX2024000806A (es) | Composiciones y métodos para prevenir y/o tratar enfermedades asociadas con la expresión de la interleuquina 23 (il-23). | |
| MX2025013695A (es) | Método para administrar un modulador dirigido al receptor 1 de esfingosina-1-fosfato y receptor 4 de esfingosina-1-fosfato (s1pr1 y s1pr4) | |
| IL311561A (en) | Polyacrylamide hydrogel for use in the treatment and/or prevention of osteoarthritis | |
| MD3250G2 (ro) | Metodă de tratament al sindromului cheroto-conjunctivitei sica | |
| TW200640460A (en) | HIV integrase inhibitors |